A director at AstraZeneca sold 7,500 shares at 177.269USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
A director at Hikma Pharmaceuticals bought 530,000 shares at 1,579p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
With the baxdrostat P3 to be published on 30th August, we show that AZN’s pipeline upside is underappreciated, in part due to the significant complexity & sheer volume of readouts. We also show that Imfinzi peak sales are likely too low; we are $2bn higher than consensus in 2029. We expect consensus forecasts to materially increase after the full baxdrostat data on the 30th August, we are ~$2bn higher than consensus and see upside risk to our forecasts. AZN’s catalyst path is one of the best in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.